liposomal amphotericin B + miltefosine

DRUG2 trials

Sponsors

Drugs for Neglected Diseases

Conditions

Primary Visceral LeishmaniasisVisceral Leishmaniasis

Phase 2

Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa

CompletedNCT01067443

Drugs for Neglected DiseasesPrimary Visceral Leishmaniasis

Start: 2010-03-31End: 2011-06-30Updated: 2017-04-24

Phase 3

Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh

CompletedNCT01122771

Drugs for Neglected DiseasesVisceral Leishmaniasis

Start: 2010-05-31End: 2014-03-31Updated: 2016-01-21

Related Papers

Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial

Clinical Infectious Diseases2018-08-2853 citations

Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh

PLoS neglected tropical diseases2017-05-3073 citations

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial

PLoS neglected tropical diseases2016-09-14103 citations

Generalizing boundaries for triangular designs, and efficacy estimation at extended follow-ups

Trials2015-11-162 citations

Safety and efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial.

2011-06-3037 citations